Trials / Completed
CompletedNCT00447694
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2\* in beta-thalassemia patients with deferasirox treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferasirox | Oral deferasirox 30mg/kg/day once per day for 77 weeks. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2007-03-15
- Last updated
- 2021-06-14
- Results posted
- 2021-06-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00447694. Inclusion in this directory is not an endorsement.